Richard Pazdur (Flatiron Health via YouTube)

Ed­i­to­r­i­al: Did Rick Paz­dur's big 'no' on Lil­ly's Chi­na-born PD-1 al­so spell the end for price dis­rup­tion?

Eli Lil­ly has a big de­ci­sion com­ing Thurs­day as an FDA ad­vi­so­ry com­mit­tee con­sid­ers the mer­its of PD-1 block­er sin­til­imab, a drug de­vel­oped in Chi­na …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.